 <h1>Burosumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to burosumab: subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, burosumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking burosumab:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>bone malformations</li>
<li>confusion</li>
<li>cough or hoarseness</li>
<li>fast or irregular heartbeat</li>
<li>fever</li>
<li>frequent bone fractures</li>
<li>hives, itching, skin rash</li>
<li>irritation</li>
<li>joint pain, stiffness, or swelling</li>
<li>mood or mental changes</li>
<li>muscle cramps in the hands, arms, feet, legs, or face</li>
<li>numbness and tingling around the mouth, fingertips, or feet</li>
<li>pain in the arm or leg</li>
<li>redness of the skin</li>
<li>seizures</li>
<li>slowed growth</li>
<li>stomach cramps</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>tightness in the chest</li>
<li>tremor</li>
<li>troubled breathing or swallowing</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of burosumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Aching or discomfort in the lower legs or sensation of crawling in the legs</li>
<li>back pain</li>
<li>constipation</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>dizziness</li>
<li>headache</li>
<li>muscle ache, pain, spasm, or stiffness</li>
<li>nausea</li>
<li>toothache</li>
<li>vomiting</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to burosumab: subcutaneous solution</i></p><h3>General</h3><p>The most commonly reported adverse reactions in pediatric patients have included injection site reactions, vomiting, pyrexia, and extremity pain.  In adult patients, back pain, tooth infection, restless leg syndrome, dizziness, and constipation have been reported.  In both adults and pediatric patients, headache and decreased vitamin D has been reported.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Vitamin D decreased (up to 37%) </p>
<p><b>Common</b> (1% to 10%): Blood phosphorus increased</p><p>Increased blood phosphorus was reported in 6% of adult patients during clinical trials.  There were no reports of increased blood phosphorus in pediatric clinical trials.</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Vomiting (up to 48%), toothache (up to 23%), tooth abscess (up to 34%), dental caries (up to 31%), diarrhea (up to 24%), constipation (up to 17%) </p>
<p><b>Common</b> (1% to 10%): Nausea</p><h3>Hypersensitivity</h3><p>In pediatric patients, the more frequent events that were considered potential hypersensitivity events included rash (22%), injection site rash (6%), and urticaria (5%).  In adult patients approximately 6% of patients in both the study group and placebo group experience mild or moderate hypersensitivity reactions that did not require drug discontinuation.</p><p><b>Frequency not reported</b>: Hypersensitivity reactions</p><h3>Dermatologic</h3><p>Rash includes pruritic, maculopapular, and pustular rashes</p><p><b>Very common</b> (10% or more): Rash (up to 27%)</p><h3>Musculoskeletal</h3><p>Spinal stenosis is common in adults with X-linked hypophosphatemia (XLH).  In phase 2/3 studies, 6 patients (n=176) underwent spinal surgery for what appeared to involve progression of a preexisting spinal stenosis.  It is unknown if therapy exacerbates spinal stenosis or spinal cord compression.</p><p><b>Very common</b> (10% or more): Extremity pain (up to 46%), myalgia (up to 17%), back pain (15%) </p>
<p><b>Common</b> (1% to 10%): Spinal surgery</p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (up to 55%)</p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site reaction (up to 67%)</p><p>Injection site reactions have included erythema, pruritus, swelling, pain, rash, bruising, discoloration, discomfort, hematoma, hemorrhage, induration, macule, and urticaria at the injection site</p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 73%), dizziness (up to 15%), restless leg syndrome (12%)</p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (up to 52%)</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Crysvita (burosumab)." Ultragenyx Pharmaceutical, Novato, CA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What conditions is Crysvita (burosumab-twza) used to treat?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about burosumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous metabolic agents</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Burosumab-twza Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Crysvita</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>X-Linked Hypophosphatemia</li>
<li>Osteomalacia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to burosumab: subcutaneous solution</i></p><h3>General</h3><p>The most commonly reported adverse reactions in pediatric patients have included injection site reactions, vomiting, pyrexia, and extremity pain.  In adult patients, back pain, tooth infection, restless leg syndrome, dizziness, and constipation have been reported.  In both adults and pediatric patients, headache and decreased vitamin D has been reported.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Vitamin D decreased (up to 37%) </p><p><b>Common</b> (1% to 10%): Blood phosphorus increased</p><p>Increased blood phosphorus was reported in 6% of adult patients during clinical trials.  There were no reports of increased blood phosphorus in pediatric clinical trials.</p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Vomiting (up to 48%), toothache (up to 23%), tooth abscess (up to 34%), dental caries (up to 31%), diarrhea (up to 24%), constipation (up to 17%) </p><p><b>Common</b> (1% to 10%): Nausea</p><h3>Hypersensitivity</h3><p>In pediatric patients, the more frequent events that were considered potential hypersensitivity events included rash (22%), injection site rash (6%), and urticaria (5%).  In adult patients approximately 6% of patients in both the study group and placebo group experience mild or moderate hypersensitivity reactions that did not require drug discontinuation.</p><p><b>Frequency not reported</b>: Hypersensitivity reactions</p><h3>Dermatologic</h3><p>Rash includes pruritic, maculopapular, and pustular rashes</p><p><b>Very common</b> (10% or more): Rash (up to 27%)</p><h3>Musculoskeletal</h3><p>Spinal stenosis is common in adults with X-linked hypophosphatemia (XLH).  In phase 2/3 studies, 6 patients (n=176) underwent spinal surgery for what appeared to involve progression of a preexisting spinal stenosis.  It is unknown if therapy exacerbates spinal stenosis or spinal cord compression.</p><p><b>Very common</b> (10% or more): Extremity pain (up to 46%), myalgia (up to 17%), back pain (15%) </p><p><b>Common</b> (1% to 10%): Spinal surgery</p><h3>Other</h3><p><b>Very common</b> (10% or more): Pyrexia (up to 55%)</p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site reaction (up to 67%)</p><p>Injection site reactions have included erythema, pruritus, swelling, pain, rash, bruising, discoloration, discomfort, hematoma, hemorrhage, induration, macule, and urticaria at the injection site</p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 73%), dizziness (up to 15%), restless leg syndrome (12%)</p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (up to 52%)</p><p id="ref_1">1. "Product Information. Crysvita (burosumab)." Ultragenyx Pharmaceutical, Novato, CA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What conditions is Crysvita (burosumab-twza) used to treat?</li>
</ul><h2>More about burosumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: miscellaneous metabolic agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Burosumab-twza Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>X-Linked Hypophosphatemia</li>
<li>Osteomalacia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>